The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Thursday preview: US CPI, AstraZeneca in focus

Wed, 09th Feb 2022 18:32

(Sharecast News) - Investors' attention will be firmly on the latest consumer price due out in the US covering the month of January.
The Department of Labor is expected to report that the annual rate of consumer price inflation accelerated from a clip of 7.1% in December to 7.3%.

Core CPI is also expected to have picked up the pace, from 5.5% to 5.9%.

Meanwhile, the market spotlight in Europe will be on speeches from European Central Bank vice-president, Luis de Guindos, and the bank's chief economist, Philip Lane, at 1200 GMT and 1315 GMT, respectively.

Against that backdrop, officials at Sweden's central bank will make a policy announcement at 0830 GMT.

On home shores, overnight the Royal Institute of Chartered Surveyors will release its house price balance for the month of January.

Further afield, in Indonesia, rate-setters are due to meet to decide on monetary policy with the consensus being that the seven-day reverse repurchase rate will be unchanged at 3.50%.

In the corporate space, and for AstraZeneca's fourth quarter numbers, UBS analyst Michael Leuchten says that investors' focus will be on the performance of the underlying business following the acquisition of Alexion mid-year.

Their attention will also be on the key drivers of the drug giant's top-line growth, sales of Tagrisso, Lynparza and Imfinzi, all of which fell short of analysts' estimates in the third quarter.

So too, Leuchten added, investors were keen for additional commentary around the company's latest clinical success, the PROPEL trial for Lynparza.

For the fourth quarter, Leuchten had penciled in a 52.9% jump in sales to approximately $11.33bn for a 61.8% surge in core earnings before interest and tax to $3.07bn.

Thursday 10 February

INTERIMS

Ashmore Group, MJ Gleeson , Redrow

INTERIM DIVIDEND PAYMENT DATE

Ashtead Group

INTERIM EX-DIVIDEND DATE

Henderson Smaller Companies Inv Trust

QUARTERLY EX-DIVIDEND DATE

Custodian Reit , ICG Enterprise Trust, INTERNATIONAL BUSINESS MACHINES CORPORATION COM STK USD0.20 (CDI), The Renewables Infrastructure Group Limited

INTERNATIONAL ECONOMIC ANNOUNCEMENTS

Consumer Price Index (US) (13:30)

Continuing Claims (US) (13:30)

Initial Jobless Claims (US) (13:30)

Q4

AstraZeneca, Unilever

GMS

SEC Newgate S.P.A. NPV (CDI)

FINALS

AstraZeneca, PJSC MNC Norilsk Nickel ADR, Relx plc, Unilever

SPECIAL DIVIDEND PAYMENT DATE

Unicorn AIM VCT

AGMS

Benchmark Holdings , easyJet, Tritax Eurobox (GBP)

TRADING ANNOUNCEMENTS

Royal Mail, Watches of Switzerland Group

UK ECONOMIC ANNOUNCEMENTS

Balance of Trade (07:00)

GDP (Preliminary) (07:00)

Gross Domestic Product (07:00)

Index of Services (07:00)

Industrial Production (07:00)

Manufacturing Production (07:00)

RICS Housing Market Survey (00:01)

FINAL DIVIDEND PAYMENT DATE

Hargreave Hale AIM VCT , Sage Group, Smiths News , Unicorn AIM VCT

FINAL EX-DIVIDEND DATE

Aberforth Smaller Companies Trust, Avon Protection, Impax Asset Management Group, Virgin Money UK
More News
Today 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.